Abstract
This study contains the synthesis, spectral analysis, and the enzyme inhibition effects of the Pd-based complexes bearing both 2-aminopyridine and N-heterocyclic carbene (NHC) ligands. The NHC ligand in the Pd-based complexes contains the 3-cyanobenzyl group. All new complexes were synthesized from (NHC)PdBr2(pyridine) complexes and 2-aminopyridine. These new complexes were characterized by using elemental analysis, 1H NMR, 13C NMR, and FT-IR spectroscopy techniques. Furthermore, inhibitor effects of these complexes were also tested toward some metabolic enzymes such as carbonic anhydrase and xanthine oxidase enzymes. The IC50 range for hCA I, hCA II, and XO were determined as 0.325–0.707, 0.238–0.636, and 0.576–1.693 μM, respectively. These data showed that Pd(II)–NHC complexes bearing 2-aminopyridine may be potent inhibitors of hCA and XO enzymes. Besides these applications, molecular docking was performed by using CDOCKER tool as a part of Discovery studio 2019, not only to determine the binding mode of synthesized inhibitors, but also to determine the correlation between the CDOCKER score values and IC50 values. We found a good correlation (R2 = 0.7403) between IC50 and the CDOCKER score of the inhibitors for XO. These findings could be a reference to start the development of effective medicine for XO.
Graphic abstract
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
Since half a century ago, the NHCs have attracted a great deal of interest as ligands in the fields of organic and organometallic chemistry after the discovery of the stable metal–NHC complexes by Wanzlick [1]. Surprisingly, NHCs have been overshadowed by metal-NHC complexes for 23 years. In the early 1990s, stable, isolated and storable crystal NHC 1,3-di(adamantyl)imidazol-2-ylidene (IAd) was reported by Arduengo et al. [2, 3].
The NHCs have important properties such as high reactivity, structural diversity, being a strong σ-donor and a weak π-acceptor. Furthermore, the stability of the metal–carbene bond in the metal–NHC complexes increased the interest in these complexes [4,5,6,7,8,9]. The NHCs can form stable complexes with almost all transition metals. Stable metal–NHC complexes of many transition metals such as Pt [10], Ru [11, 12], Pd [13], Fe [14], Ni [15], Co [16], Zn [17], Mn [18], Hg [19], Ag [20], Cu [21], and Au [22] have already been synthesized. In the beginning, the synthesized metal–NHC complexes were used as active catalysts in various catalytic reactions [23,24,25,26,27]. Subsequently, biochemists have become interested in the biological properties of these complexes [28, 29]. In particular, studies on the medical applications of the metal–NHC complexes containing the Au [30], Ru [31], Pt [32], and Ag [33] transition metals have increased. Recently, studies on the medical applications of Pd(II)NHC complexes have been published [28, 29, 34,35,36]. However, there is only one recent study concerning the medical applications of Pd-based complexes containing both 2-aminopyridine and NHC ligands [29].
Carbonic anhydrase (CA) is a zinc metalloenzyme that plays an important role in biological systems [37]. CAs are also vital in maintaining physiological and pathophysiological processes. Therefore, the inhibition of CAs is a useful way for healing some disease such as cancer [38], and obesity cases [39]. CA catalyzes the conversion to HCO3− by giving the proton of H2O to CO2. Thus, it keeps up the acid–base balance in the blood and other tissues and helps to move out CO2 from biological systems [40], ion exchange, and cardiovascular system organization [41]. Whereas the inhibitors-oriented hCA I are beneficial in retinal and cerebral edema, inhibitors-oriented hCA II are utilized as diuretics, in edema management, as antiglaucoma substances, anti-epilepsy drugs, and additionally for altitude sickness therapy [42].
Xanthine oxidase (XO, EC 1.17.3.2) is a flavor-protein enzyme and has high activity in the liver and intestine. XO is highly concentrated in the gastrointestinal tract [43]. XO is an enzyme that has major activities such as the hydroxylation of hypoxanthine to xanthine and xanthine to uric acid [44]. During the reaction process, an increase in reactive oxygen species (ROS) level is considered [45]. Therefore, XO is an important source of ROS and uric acid. Excessive manufacture of uric acid may cause hyperuricemia, which is the key for gout disease [46]. The increment of XO level can give rise to oxidative stress, mutagenesis, and perhaps cause cancer. Because of these, inhibition of XO decreases oxidative stress immediately after inflammation. Furthermore, the inhibition of XO may be a way for cancer cure [47].
We had previously synthesized Pd-based complexes bearing the PPh3/NHC [8, 27, 48], and the morpholine/NHC ligand mixture [28]. In this study, we have synthesized new Pd-based complexes bearing NHC/2-aminopyridine ligand mixture from Pd-PEPPSI (pyridine-enhanced precatalyst preparation stabilization and initiation) complexes and 2-aminopyridine. These new complexes contain two important functional groups, such as benzonitrile (–C6H5CN) and aminopyridine (–C5H4NNH2). The benzonitrile core present in many chemical structures such as natural products, pharmaceuticals, and agrochemicals makes such molecules interesting targets among many chemicals [49, 50]. Moreover, the nitrile group in benzonitriles represents one of the most commonly used functional groups and can be applied to other functional groups such as aldehydes, carboxylic acids, amidines, amides, and amines [51]. The complexes containing electrophilic groups such as benzonitriles, commonly referred to as “warhead”, have been used in the design of some enzyme inhibitors [52, 53]. The aminopyridine group performs electronic interactions thanks to its nucleophilic character, while it can form hydrogen bond interaction with organic molecules due to its amino group. In addition, the pharmacokinetic properties of molecules containing the aminopyridine group largely depend on their lipophilicity and pKA values [54]. Recently, Krasavin et al. reported that aminonitriles can act as true inhibitors in hCA II inhibition [55]. Fouda et al. informed that in the topoisomerase catalytic activity analysis of β-enaminonitriles, these compounds inhibit both topoisomerases I and II enzymes [56]. Herein, the enzyme inhibition effects of the (NHC)PdBr2(2-aminopyridine) complexes bearing benzonitrile-substituted NHC and 2-aminopyridine ligand on the carbonic anhydrase enzymes (hCA I and hCA II) and xanthine oxidase enzyme were investigated. Also, a molecular docking study was conducted to clarify the interaction of the complexes with enzymes in this study.
Results and discussion
Synthesis
The new Pd-based complexes 1a–1f which contain both 2-aminopyridine and NHC ligand mixture are illustrated in Scheme 1. All complexes were synthesized from the starting material (NHC)PdBr2(pyridine) complexes [57] and 2-aminopyridine. The pyridine ligand is weakly attached to the palladium center in the starting material (NHC)PdBr2(pyridine) complexes [58]. The 2-aminopyridine ligand, which has a stronger nucleophilic character than pyridine, is attached to the palladium metal center via nucleophilic addition, while the pyridine which has a weak nucleophilic character is eliminated from the palladium center. Thus, stable (NHC)PdBr2(2-aminopyridine) complexes 1a–1f were synthesized as a result of the nucleophilic substitution reaction. All new (NHC)PdBr2(2-aminopyridine) complexes bearing the 3-cyanobenzyl group 1a–1f were obtained as a yellow solid in good yields between 76 and 82%. The formation of all complexes 1a–1f was confirmed by using FT-IR, 1H NMR, 13C NMR spectroscopic methods, and elemental analysis. When the 1H NMR spectra of the (NHC)PdBr2(2-aminopyridine) complexes 1a–1f were examined, the appearance of the methylene (–CH2) protons for the benzyl groups next to nitrogen atoms were observed as sharp singlets in the range of 6.10 ppm and 6.39 ppm. The appearance of the amino (–NH2) protons in the 2-aminopyridine between 5.30 and 6.02 ppm proved the successful synthesis. Following this, the aromatic (C–H) protons in the 2-aminopyridine groups next to nitrogen atom were observed in the range of 6.43 ppm and 6.70 ppm. The rest of the aromatic protons were observed as multiplets between 6.47 ppm and 8.08 ppm. Examination of the 13C NMR spectra of the stable (NHC)PdBr2(2-aminopyridine) complexes 1a–1f revealed the methylene carbons (–CH2) on the benzyl groups within 49.8–53.6 ppm range. The characteristic carbene (NCN) peaks for the complexes 1a–1f were between 165.8 and 168.1 ppm. The characteristic nitrile (Ar–CN) carbon peaks for the complexes 1a–1f were observed between 117.4 and 124.0 ppm. Following this, the aromatic carbons in the 2-aminopyridine groups next to nitrogen atom were observed between 157.1 ppm and 160.2 ppm. The rest of the aromatic carbons were in the range of 110.9–139.6 ppm. All the 1H and 13C NMR spectral details are given in the experimental section. The peaks at 1447, 1446, 1447, 1446, 1447, and 1444 cm−1 (respectively) in the FT-IR spectra verified clearly the presence of ν(CN for 2-Carbene) in the new complexes 1a–1f. The peaks at 1628, 1626, 1627, 1626, 1626, and 1626 cm−1 (respectively) in the FT-IR spectra proved clearly the presence of ν(CN for amino) in the new complexes 1a–1f. The peaks at 2323, 2231, 2228, 2231, 2228, and 2224 cm−1 (respectively) in the FT-IR spectrums demonstrated clearly the presence of ν(CN for nitrile) in the new complexes 1a–1f. The peaks at 3319, 3332, 3351, 3332, 3336, and 3329 cm−1 (respectively) in the FT-IR spectra showed clearly the presence of ν(NH) in the new complexes 1a–1f. All spectral data results are consistent with the literature [29].
Enzyme inhibition studies
The inhibition properties of novel (NHC)PdBr2(2-aminopyridine) complexes were investigated on hCA I and hCA II by using the esterase assay method and the IC50 values for hCA I and hCA II are summarized in Table 1 and Fig. 1. Isoenzymes hCA I and hCA II are found in red blood cell (RBC) and needed for maintaining the physiological pH of the blood when the level of (HCO3−) increases [46]. In this study, the IC50 ranges were determined as 0.325–0.707 μM for hCA I and 0.238–0.636 μM for hCA II. In a recent study, a novel series of diamide-based benzenesulfonamides demonstrated the IC50 for hCAI in the range from 0.796 to 8.175 μM and for hCA II in the range from 0.068 to 0.448 μM [59]. In another study, a new series of β-aminochalcogenides were synthesized and the IC50 values determined in the range from 4.6 to 22.1 μM for hCAI [60]. In addition, they newly synthesized quinazoline-linked benzensulfonamides and found the IC50 value range for hCAI (0.0394–3.665 μM) and hCA II (0.75–833.1 nM) [61]. Our results showed that all of the synthesized new 3-cyanobenzyl-substituted (NHC)PdBr2(2-aminopyridine) complexes effectively inhibited hCA I and hCA II. Due to the high inhibitor activity of (NHC)PdBr2(2-aminopyridine) complexes toward CA isoenzymes, it might be used as an interesting therapeutic which could be utilized for the treatment of a wide number of disorders such as oxidative stress, anemia, cancer, edema, osteoporosis, and obesity [38, 39].
In vitro inhibition effect of (NHC)PdBr2(2-aminopyridine) complexes on serum bovine XO was also measured spectrophotometrically by following the increase in uric acid levels at 294 nm [47]. Allopurinol was included as a positive control to compare the IC50 values. All the NHC compounds have potential inhibition effects more than allopurinol. The IC50 for enzyme inhibition range that we found (0.576–1.693 μM) is summarized in Table 1 and Fig. 1. A recent study demonstrated the IC50 for XO (0.263–20.45 μM) for newly synthesized hesperidin derivatives [62]. In another study, a research groups synthesized coumarin derivatives, investigated the biological activity and reported that IC50 value range was 14.79–97.65 μM [63]. In another study, a series of N-(4-alkoxy-3-cyanophenyl)-isonicotinamide/nicotinamide derivatives were synthesized, evaluated for their inhibitory potency in vitro against XO and IC50 measured as 0.3–35.0 μM [64].
Recently, studies on the antibacterial and anticancer activities of novel synthesized benzonitrile-substituted NHC precursors and their silver complexes have attracted attention [63,64,65,66]. In these studies, benzonitrile-substituted NHC precursors and their silver complexes exhibited anticancer and antibacterial activity [65,66,67,68]. In these studies, benzonitrile-substituted NHC precursors and their silver complexes exhibited anticancer and antibacterial activity [65,66,67,68]. According to our results, it may be stated that metal–NHC complexes containing benzonitrile and 2-aminopyridine exhibited good biological activity in terms of enzyme inhibition properties. The benzonitrile functional group reacts easily with biological molecules such as amino acids in the enzyme structure thanks to its electronic properties. The aminopyridine group performs electronic interactions thanks to its nucleophilic character with organic molecules. Also, this group can form hydrogen bond interaction with organic molecules such as amino acid molecules due to its amino group in the structure. Other groups (aryl/alkyl) in our complexes are important in terms of secondary interaction such as electronic inductive effect and steric bulky in enzyme inhibition activity of the complexes. Our results are also parallel to those in literature [55].
Molecular docking studies
The new synthesized (NHC)PdBr2(2-aminopyridine) complexes 1a–1f were screened in vitro for their inhibition activity using different cancer targets. The xanthine oxidase enzyme (XO) and human carbonic anhydrase isoenzymes (hCA I and hCA II) were employed for these comparative studies through molecular docking using Discovery Studio 2019. The hydrophilic and hydrophobic interactions of allopurinol in binding site of XO formed noticeable important residues such as Ser876, Glu879, Arg880, Phe 914, Phe1009, Ala1078, and Ala1079. In line with this result, the binding pattern of ligands was carefully investigated and evaluated. At the same time, the in vitro data of the related ligands are helpful to compare with their computational results.
The first attention case is that all the ligands are quite effective compared to the reference ligand against the XO target based on their in vitro data. This was easily explained with the help of molecular docking results. Based on the structure of allopurinol, which is expressed in yellow, the related ligands have a larger surface area, as seen in Fig. 2. For this reason, they have more interactions (electrostaic and hydrophobic) in the binding site of the target, especially, 1e and 1f complexes, which have better inhibition effects than reference ligand and others (1a–1d), show supporting results in Fig. 2 and Table S1.
The complex 1f can be compared with active complex 1e; the optimum number (three) and positions (ortho and para) of methyl group on phenyl ring of complex 1e might be the dominant cause for the inhibition effect and these were absent in 1a, 1b, 1c, and 1d. The complex 1f has more methyl groups than 1e. But this state causes an undesired effect like less inhibition effect on XO.
Furthermore, the same process was performed to the same ligands against hCA I and hCA II. Figure 3 shows that compound 1f has the best inhibition effect than others, because it has 19 non-bonding interactions with hCA I including three hydrogen bonds with Thr199 (2.76 Å), His200 (2.11 Å), and His 67 (2.18 Å) residues of the enzyme, and also 16 hydrophobic interactions with His94, Pro3, Pro202, Ala135, Leu198, Trp5, Tyr20,His67, and His200 residues in the binding site of hCA I. The molecular docking results obtained for hCA II are similar to those obtained with the XO target in Fig. 4.
Besides interactions of the ligands, binding energy values of the (NHC)PdBr2(2-aminopyridine) complexes 1a–1f on each target were calculated and analyzed as given in Table 2.
Further, the correlation between the binding energy values of the studied compounds and inhibition constant IC50 values was studied and plotted in Fig. 5, which displays a linear relationship. In the analysis of CDOCKER docking results, a high correlation (R2 = 0.7403) between IC50 of the studied compounds against XO and binding energy was seen as shown in Fig. 5a. In the case of hCA II, the correlation between IC50 and binding energy was moderate, R2 = 0.5021 (Fig. 5c), whereas a poor correlation (R2 = 0.025) was identified between binding energy and IC50 of hCA I ,as illustrated in Fig. 5b. Therefore, binding energy has the best capability to rank the bioactivities of the studied inhibitors for XO; this finding is consistent with that of Yan et al. [69], who reported that binding energy was in good correlation (R2 = 0.7236) with IC50 of the ligands as inhibitors for COX-2. But binding energy is not the best choice for both hCA I and hCA II. The findings of this study could be promising in the future for development of effective drug for XO.
Conclusions
Consequently, this study contains the synthesis and inhibitor applications of the new 3-cyanobenzyl-substituted (NHC)PdBr2(2-aminopyridine) complexes. All of the new complexes were characterized using FT-IR spectroscopy, 1H NMR, 13C NMR and elemental analysis techniques. The characterization data were consistent with the proposed formulas. The new (NHC)PdBr2(2-aminopyridine) complexes 1a–1f were used to determine the efficient inhibition against CA isoenzymes, and xanthine oxidase (XO) enzymes. Therefore, these complexes may be effective inhibitors of hCA and XO enzymes due to nano- and micromolar levels of IC50. Also, the docking calculations exhibited favorable binding between the new (NHC)PdBr2(2-aminopyridine) complexes 1a–1f and three targets. The results of the docking studies based on the related new (NHC)PdBr2(2-aminopyridine) complexes 1a–1f with three targets, including XO and hCA I and hCA II, confirmed the experimental data. The impact of these compounds on binding sites of XO, hCA I, and hCA II was carefully investigated and interpreted according to their interactions types and binding energy value using molecular docking.
Experimental
All synthesis for the new Pd-based complexes 1a–1f containing both 2-aminopyridine and NHC ligand mixture were prepared under an inert argon atmosphere by using standard Schlenk techniques. All solvents were used without any drying or purification. All reagents were economically accessible from Alfa Aesar, Sigma-Aldrich, AFG Bioscience, Merck, and Acros Organics Chemical Co., and utilized without subsequent purification. The synthesis of meta-cyanobenzyl-substituted Pd-PEPPSI complexes [57] used as the starting material in this study was synthesized in Inonu University Catalysis Research and Application Center Laboratory. Furthermore, melting points were recognized in glass capillaries under air with an Electrothermal-9200 melting point apparatus. On the other hand, FT-IR spectra assays were kept in the range 400–4000 cm−1 on Perkin Elmer Spectrum 100 FT-IR spectrometer using KBr discs. Carbon (13C) and proton (1H) NMR spectra were recorded using either a Bruker Avance III 400 MHz NMR spectrometer operating at 100 MHz (13C), 400 MHz (1H) in DMSO-d6 and CDCl3 with tetramethylsilane as an internal reference by Inonu University Catalysis Research and Application Center. Elemental analyses were performed by Inonu University Scientific and Technology Centre (Malatya, Turkey).
Dibromo[1-benzyl-3-(3-cyanobenzyl)benzimidazol-2-ylidene](2-aminopyridine)palladium(II) (1a, C27H23Br2N5Pd)
The complex 1a was synthesized from the reaction of 134 dibromo[1-benzyl-3-(3-cyanobenzyl)benzimidazol-2-ylidene]pyridinepalladium(II) (0.2 mmol) and 24 mg 2-aminopyridine (0.25 mmol) in 15 cm3 chloroform at room temperature at 3 h [29]. Yield: 96 mg (79%); m.p.: 207–208 °C; IR (KBr): \(\overline{\nu }\) = 3319 (NH), 2323 (C≡N for nitrile), 1628 (C–N for amino), 1447 (C–N for 2-Ccarbene) cm−1; 1H NMR (400 MHz, DMSO-d6): δ = 8.32 (d, 1H, J = 4.8 Hz, –NC5H4NH2), 7.95–7.31 (m, 14H, Ar–H), 6.68 (m, 2H, –NC5H4NH2), 6.36 (s, 2H, –NCH2C6H4CN), 6.30 (s, 2H, –NCH2C6H5), 6.02 (s, 2H, –NC5H4NH2) ppm; 13C NMR (100 MHz, DMSO-d6): δ = 168.1 (Pd–Ccarbene), 159.3 (amino-pyr C1), 151.4 (amino-pyr C5), 139.6, 136.5, 136.3, 136.1, 135.1, 134.0, 131.3, 129.1, 128.6, 125.5 (Ar–C), 124.0 (C≡N), 112.2 (amino-pyr C4), 112.1(amino-pyr C3), 111.4 (Ar–C), 108.7 (amino-pyr C2), 52.2 (–NCH2C6H4CN), 51.8 (–NCH2C6H5) ppm.
Dibromo[1-(3-cyanobenzyl)-3-(2-methylbenzyl)benzimidazol-2-ylidene](2-aminopyridine)palladium(II) (1b, C27H23Br2N5Pd)
The complex 1b was synthesized by using the same method mentioned for 1a, using 137 mg dibromo[1-(3-cyanobenzyl)-3-(2-methylbenzyl)benzimidazol-2-ylidene]pyridinepalladium(II) (0.2 mmol). Yield: 104 mg (76%); m.p.: 228–229 °C; IR (KBr) \(\overline{\nu }\) = 3332 (NH), 2331 (C≡N for nitrile), 1626 (C–N for amino), 1446 (C–N for 2-Ccarbene) cm−1; 1H NMR (400 MHz, DMSO-d6): δ = 8.18 (s, 1H, –NC5H4NH2), 8.06–7.07 (m, 13H, Ar–H), 6.64 (m, 2H, –NC5H4NH2), 6.39 (s, 2H, –NCH2C6H4CN), 6.25 (s, 2H, –NCH2C6H4CH3), 5.90 (s, 2H, –NC5H4NH2), 2.59 (s, 3H, –NCH2C6H4CH3) ppm; 13C NMR (100 MHz, DMSO-d6): δ = 168.0 (Pd–Ccarbene), 159.1 (amino-pyr C1), 149.0 (amino-pyr C5), 137.9, 134.7, 134.0, 133.9, 132.2, 130.3, 127.9, 124.1, 122.9 (Ar–C), 119.1 (C≡N), 112.8 (amino-pyr C3), 112.0 (amino-pyr C4), 111.4 (Ar–C), 105.3 (amino-pyr C2), 51.7 (–NCH2C6H4CN), 50.3 (–NCH2C6H4CH3), 19.8 (–NCH2C6H4CH3) ppm.
Dibromo[1-(3-cyanobenzyl)-3-(3-methylbenzyl)benzimidazol-2-ylidene](2-aminopyridine)palladium(II) (1c, C28H25Br2N5Pd)
The complex 1c was synthesized by using the same method mentioned for 1a, using 137 mg dibromo[1-(3-cyanobenzyl)-3-(3-methylbenzyl)benzimidazol-2-ylidene]pyridine palladium(II) (0.2 mmol). Yield: 112 mg (80%); m.p.: 170–171 °C; IR (KBr) \(\overline{\nu }\) = 3351 (NH), 2228 (C≡N for nitrile), 1627 (C–N for amino), 1447 (C–N for 2-Ccarbene) cm−1; 1H NMR (400 MHz, CDCl3): δ = 8.27 (s, 1H, –NC5H4NH2), 7.91–7.07 (m, 13H, Ar–H), 6.63, 6.51 (s, 2H, –NC5H4NH2), 6.23 (s, 2H, –NCH2C6H4CN), 6.16 (s, 2H, –NCH2C6H4CH3), 5.34 (s, 2H, –NC5H4NH2), 2.35 (s, 3H, –NCH2C6H4CH3) ppm; 13C NMR (100 MHz, CDCl3): δ = 167.1 (Pd–Ccarbene), 158.2 (amino-pyr C1), 152.6 (amino-pyr C5), 149.4 (amino-pyr C5), 138.7, 134.8, 134.4, 132.5, 132.1, 131.5, 129.9, 129.1, 128.8, 125.1, 123.7, 123.6 (Ar–C), 118.4 (C≡N), 114.3 (Ar–C), 113.0 (amino-pyr C3), 111.8 (amino-pyr C4), 111.4 (Ar–C), 110.8 (amino-pyr C2), 53.6 (–NCH2C6H4CN), 52.3 (–NCH2C6H4CH3), 21.4 (–NCH2C6H4CH3) ppm.
Dibromo[1-(3-cyanobenzyl)-3-(4-methylbenzyl)benzimidazol-2-ylidene](2-aminopyridine)palladium(II) (1d, C28H25Br2N5Pd)
The complex 1d was synthesized by using the same method mentioned for 1a, using 137 mg dibromo[1-(3-cyanobenzyl)-3-(4-methylbenzyl)benzimidazol-2-ylidene]pyridine palladium(II) (0.2 mmol). Yield: 109 mg (78%); m.p.: 215–216 °C; IR (KBr) \(\overline{\nu }\) = 3332 (NH), 2231 (C≡N for nitrile), 1626 (C–N for amino), 1446 (C–N for 2-Ccarbene) cm−1; 1H NMR (400 MHz, CDCl3): δ = 8.21 (m, 1H, –NC5H4NH2), 7.84–7.05 (m, 13H, Ar–H), 6.56, 6.43 (d, m, 2H, J = 8.4 Hz, –NC5H4NH2), 6.15 (s, 2H, –NCH2C6H4CN), 6.11 (s, 2H, –NCH2C6H4CH3), 5.30 (s, 2H, –NC5H4NH2), 2.28 (s, 3H, –NCH2C6H4CH3) ppm; 13C NMR (100 MHz, CDCl3): δ = 165.8 (Pd–Ccarbene), 157.1 (amino-pyr C1), 148.3 (amino-pyr C5), 137.7, 137.1, 135.6, 131.5, 131.0, 130.6, 130.4, 128.9, 128.6, 127.0, 122.6, 122.5 (Ar–C), 117.4 (C≡N), 113.3 (amino-pyr C3), 112.0 (amino-pyr C3), 110.9 (Ar–C), 110.4 (amino-pyr C4), 109.7 (amino-pyr C2), 52.6 (–NCH2C6H4CN), 51.3 (–NCH2C6H4CH3), 20.2 (–NCH2C6H4CH3) ppm.
Dibromo[1-(3-cyanobenzyl)-3-(2,4,6-trimethylbenzyl)benzimidazol-2-ylidene](2-aminopyridine)palladium(II) (1e, C28H25Br2N5Pd)
The complex 1e was synthesized by using the same method mentioned for 1a, using 142 mg dibromo[1-(3-cyanobenzyl)-3-(2,4,6-trimethylbenzyl)benzimidazol-2-ylidene]pyridine palladium(II) (0.2 mmol). Yield: 114 mg (82%); m.p.: 232–231 °C; IR (KBr) \(\overline{\nu }\) = 3336 (NH), 2228 (C≡N for nitrile), 1626 (C–N for amino), 1447 (C–N for 2-Ccarbene) cm−1; 1H NMR (400 MHz, DMSO-d6): δ = 8.13 (s, 1H, –NC5H4NH2), 7.99–6.89 (m, 9H, Ar–H), 6.67, 6.61 (s, d, 2H, J = 8.1 Hz, –NC5H4NH2), 6.48 (s, 2H, –NCH2C6H2(CH3)3), 6.38 (s, 2H, –NCH2C6H4CN), 6.10 (s, 2H, –NCH2C6H2(CH3)3), 5.89 (s, 2H, –NC5H4NH2), 2.36, 2.32 (s, 9H, –NCH2C6H2(CH3)3) ppm; 13C NMR (100 MHz, DMSO-d6): δ = 167.2 (Pd–Ccarbene), 159.1 (amino-pyr C1), 149.0 (amino-pyr C5), 148.2 (amino-pyr C3), 138.5, 138.1, 137.9, 135.0, 133.9, 133.3, 132.2, 130.2, 130.0, 128.7, 123.8 (Ar–C), 119.1 (C≡N), 112.6 (amino-pyr C4), 112.0 (amino-pyr C4), 111.5 and 111.3 (Ar–C), 108.4 (amino-pyr C2), 51.8 (–NCH2C6H4CN), 49.8 (–NCH2C6H2(CH3)3), 21.2 (–NCH2C6H2(CH3)3) ppm.
Dibromo[1-(3-cyanobenzyl)-3-(2,3,4,5,6-pentamethylbenzyl)benzimidazol-2-ylidene](2-aminopyridine)palladium(II) (1f, C30H29Br2N5Pd)
The complex 1f was synthesized by using the same method mentioned for 1a, using 148 mg dibromo[1-(3-cyanobenzyl)-3-(2,3,4,5,6-pentamethylbenzyl)benzimidazol-2-ylidene]pyridine palladium(II) (2 mmol). Yield: 115 mg (79%); m.p.: 246–247 °C; IR (KBr) \(\overline{\nu }\) = 3329 (NH), 2224 (C≡N for nitrile), 1626 (C–N for amino), 1444 (C–N for 2-Ccarbene) cm−1; 1H NMR (400 MHz, DMSO-d6): δ = 8.14 (s, 1H, –NC5H4NH2), 8.08–6.47 (m, 9H, Ar–H), 6.70, 6.62 (t, m, 2H, J = 5.7 Hz, –NC5H4NH2), 6.38 (s, 2H, –NCH2C6H4CN), 6.19 (s, 2H, –NCH2C6(CH3)5), 5.90 (s, 2H, –NC5H4NH2), 2.35, 2.27 (d, s, 15H, J = 4.3 Hz, –NCH2C6(CH3)5) ppm; 13C NMR (100 MHz, DMSO-d6): δ = 167.0 (Pd–Ccarbene), 160.2 (amino-pyr C1), 159.1 (amino-pyr C1), 149.0 (amino-pyr C5), 148.1 (amino-pyr C5), 138.5, 138.1, 137.9, 137.4, 135.8, 134.4, 134.0, 133.3, 133.2, 132.2, 130.2, 128.4, 123.6 (Ar–C), 119.1 (C≡N), 112.7 (amino-pyr C3), 112.2 (amino-pyr C4), 111.9, 111.5 (Ar–C), 108.4 (amino-pyr C2), 51.8 (–NCH2C6H4CN), 51.4 (–NCH2C6(CH3)5), 17.9, 17.5, 17.2 (–NCH2C6(CH3)5) ppm.
Biochemical studies
The purification of hCA isoenzymes (hCA I and hCA II) was performed considering the methods defined previously by Göcer et al. [70]. The isoenzymes were purified via affinity column Sepharose-4B-l-tyrosine-sulfanilamide with single step. Then, the protein quantity in the purification stage was measured by Bradford method spectrophotometrically. The CA activity was assayed with the method reported by Verpoorte et al. [71]. The differences in absorbance at 348 nm of 4-nitrophenyl acetate (NPA) to 4-nitrophenylate were noted. 4-NPA was utilized as the substrate. The reaction mixture included purified enzyme, distilled water, 4-NPA (3.0 mM), and Tris–SO4 buffer (50 mM, pH 7.4). Inhibition experiments were conducted with different concentrations of the inhibitor. Table 1 and Fig. 1 show the IC50 values for the NHC.
In vitro inhibition of xanthine oxidase (ox) enzyme
The XO inhibitory effect was determined spectrophotometrically by measuring the formation of uric acid. The assay mixture contained XO enzyme (0.2 U), phosphate buffer (50 mM, pH 7.4), tested NHC, and xanthine (1 mM). After the preincubation of the assay mixture at 37 °C for 10 min, the reaction was initiated by adding freshly prepared xanthine. The formation of uric acid was measured kinetically for 2 min at 294 nm. Allopurinol was utilized as a positive control. The percentage of inhibitory activity was assayed by comparing the reaction rate of the compound-treated group to that of the positive reference. Then, IC50 of XO inhibition was calculated as follows:
Molecular docking
The present molecular docking was performed to determine the binding of the new (NHC)PdBr2(2-aminopyridine) complexes 1a–1f in three different targets, xanthine oxidase (XO) and human carbonic anhydrases (CA) having hCA I and hCA II. The CDOCKER is a grid-based molecular docking method that employs CHARMm for molecular docking. The crystal structures of XO with allopurinol as reference ligand, hCA I and hCA II were obtained from Protein Data Bank (PDB: 3NVY, 1AZM, and 3HS4, respectively). Before starting the docking process, the 3D structures were optimized by removing water molecules, metals and ligand from crystal structures. All the (NHC)PdBr2(2-aminopyridine) complexes 1a–1f were sketched and minimized using density functional theory (DFT) at B3LYP/SDD level implemented in Gaussian09 [72]. Then the conformational analysis of these complexes was analyzed using CHARMm as implemented in Discovery Studio 2019 [73]. CDOCKER was employed for molecular docking study. The results of molecular docking were evaluated depending on CDOCKER score and non-bonding interactions of each complex against the related targets.
References
Wanzlik H-W, Schönherr H-J (1968) Angew Chem Int Ed 7:141
Arduengo AJ, Harlow RL, Kline M (1991) J Am Chem Soc 113:361
Arduengo AJ, Goerlich JR, Marshall WJ (1995) J Am Chem Soc 117:11027
He X-X, Li Y, Ma B-B, Ke Z, Liu F-S (2016) Organometallics 38:2655
Crudden CM, Allen DP (2004) Coord Chem Rev 248:2247
Fortman GC, Nolan SP (2011) Chem Soc Rev 40:5151
Jana R, Pathak TP, Sigman MS (2011) Chem Rev 111:1417
Aktaş A, Barut Celepci D, Gök Y, Aygün M (2018) ChemistrySelect 3:10932
Erdemir F, Barut Celepci D, Aktaş A, Gök Y (2019) ChemistrySelect 4:5585
Wantz M, Bouché M, Dahm G, Chekkat N, Fournel S, Bellemin-Laponnaz S (2018) Int J Mol Sci 19:3472
Aktaş A, Gök Y (2014) Transit Met Chem 39:925
Aktaş A, Gök Y (2015) Catal Lett 145:631
Sarı Y, Aktaş A, Barut Celepci D, Gök Y, Aygün M (2017) Catal Lett 147:2340
Matharu AS, Ahmed S, Almonthery B, Macquarrie DJ, Lee Y-S, Kim Y (2018) Chemsuschem 11:716
Berthel JHJ, Tendera L, Kuntze-Fechner MW, Kuehn L, Radius U (2019) Eur J Inorg Chem 26:3061
Lubitz K, Radius U (2019) Organometallics 38:2558
Fliedel C, Vila-Viçosa D, Calhorda MJ, Dagorne S, Avilés T (2014) ChemCatChem 6(5):1357
Sousa SCA, Carrasco CJ, Pinto MF, Royo B (2019) ChemCatChem 11:3839
Gu W-W, Chen W-J, Yan C-G (2015) Supramol Chem 27:407
Yıldırım I, Aktaş A, Barut Celepci D, Kırbağ S, Kutlu T, Gök Y, Aygün M (2017) Res Chem Intermed 43:6379
Kuehn LA, Eichhorn F, Marder TB, Radius U (2019) J Organomet Chem 881:25
Zinser CM, Nahra F, Falivene L, Brill M, Cordes DB, Slawin AMZ, Cavallo L, Cazin CSJ, Nolan SP (2019) Chem Commun 55:6799
Aktaş A, Gök Y, Akkoç S (2013) J Coord Chem 66:2901
Erdoğan H, Aktaş A, Gök Y, Sarı Y (2018) Transit Met Chem 43:31
Gök Y, Aktaş A, Erdoğan H, Sarı Y (2018) Inorg Chim Acta 471:735
Gök Y, Aktaş A, Sarı Y, Erdoğan H (2019) J Iran Chem Soc 16:423
Erdemir F, Barut Celepci D, Aktaş A, Gök Y (2020) Chem Pap 74:99
Aktaş A, Barut Celepci D, Kaya R, Taslimi P, Gök Y, Aygün M, Gülçin İ (2019) Polyhedron 159:345
Erdemir F, Barut Celepci D, Aktaş A, Gök Y, Kaya R, Taslimi P, Demir Y, Gulçin İ (2019) Bioorg Chem 91:103134
Curado N, Giménez N, Miachin K, Aliaga-Lavrijsen M, Cornejo MA, Jarzecki AA, Contel M (2019) ChemMedChem 14:1086
Roymahapatra G, Dinda J, Mishra A, Mahapatra A, Hwang W-S, Mandal SM (2015) J Cancer Res Ther 11:105
Chekkat N, Dahm G, Chardon E, Wantz M, Sitz J, Decossas M, Lambert O, Frisch B, Rubbiani R, Gasser G, Guichard G, Fournel S, Bellemin-Laponnaz S (2016) Bioconjugate Chem 27:1942
Aktaş A, Keleştemur Ü, Gök Y, Balcıoğlu S, Ateş B, Aygün M (2017) J Iran Chem Soc 15:131
Onar G, Gürses C, Karataş MO, Balcıoğlu S, Akbay N, Özdemir N, Ateş B, Alıcı B (2019) J Organomet Chem 886:48
Hussainia SY, Haque RA, Razali MR (2019) J Organomet Chem 882:96
Hussaini SY, Haque RA, Fatima T, Agha MT, Majid AMSA, Razali MR (2018) J Coord Chem 71:2787
Gül HI, Mete E, Taslimi P, Gülçin I, Supuran CT (2017) J Enzym Inhib Med Chem 32:189
Gieling RG, Babur M, Mamnani L, Burrows N, Telfer BA, Carta F, Winum J-Y, Scozzafava A, Supuran CT, Williams KJ (2012) J Med Chem 55:5591
Arechederra RL, Waheed A, Sly WS, Supuran CT, Minteer SD (2013) Bioorg Med Chem 21:1544
Oztaşkın N, Çetinkaya Y, Taslimi P, Goksu S, Gülçin I (2015) Bioorg Chem 60:49
Bhatt A, Mahon BP, Cruzeiro VWD, Cornelio B, Laronze Cochard M, Ceruso M, Roitberg A (2017) ChemBioChem 18:213
Guler OO, Capasso C, Supuran CT (2016) J Enzym Inhib Med Chem 31:689
Al-Abbasi FA (2012) Med Sci Monit 18:208
Borges E, Fernandes E, Roleira F (2002) Curr Med Chem 9:195
Gliozzi M, Malara N, Muscoli S, Mollace V (2016) Int J Cardiol 213:23
Lü J-M, Yao Q, Chen C (2013) Biochem Pharmacol 86:1328
Springer J, Tschirner A, Hartman K, Palus S, Wirth EK, Ruis SB, Möller N, von Haehling S, Argiles JM, Köhrle J, Adams V, Anker SD, Doehner W (2012) Int J Cancer 131:2187
Aktaş A, Erdemir F, Celepci DB, Gök Y, Aygün M (2019) Transit Met Chem 44:229
Miller JS, Manson JL (2001) Acc Chem Res 34:563
Fleming FF, Wang Q (2003) Chem Rev 103:2035
Larock RC (1989) Comprehensive organic transformations: a guide to functional group preparations. VCH, New York
Powers JC, Asgian JL, Ekici ÖD, James KE (2002) Chem Rev 102:4639
Silva DG, Ribeiro JFR, De Vita D, Ciannia L, Franco CH, Lucio HF-J, Moraes CB, Rocha JR, Burtoloso ACB, Kenny PW, Leitão A, Montanari CA (2017) Bioorg Med Chem Lett 27:5031
Rodríguez-Rangel S, Bravin AD, Ramos-Torres KM, Brugarolas P, Sánchez-Rodríguez JE (2020) Sci Rep 10:52
Krasavin M, Kalinin S, Zozulya S, Griniukova A, Borysko P, Angeli A, Supuran CT (2020) J Enzym Inhib Med Chem 35:165
Fouda AM, Assiri MA, Mora A, Ali TE, Afifi TH, El-Agrody AM (2019) Bioorg Chem 93:103289
Türker F, Bereket İ, Barut Celepci D, Aktaş A, Gök Y (2020) J Mol Struct 1205:127608
Kumar A, Katari M, Ghosh P (2013) Polyhedron 52:524
Abdelrahman MA, Eldehna WM, Nocentini A, Bua S, Al-Rashood ST, Hassan GS, Bonardi A, Almehizia AA, Alkahtani HM, Alharbi A, Gratteri P, Supuran CT (2019) Int J Mol Sci 20:2484
Tanini D, Capperucci A, Supuran CT, Angeli A (2019) Bioorg Chem 87:516
El-Azab AS, Abdel-Aziz AAM, Bua S, Nocentini A, El-Gendy MA, Mohamed MA, Shawer TZ, AlSaif NA, Supuran CT (2019) Bioorg Chem 87:78
Malik N, Dhiman P, Khatkar A (2019) Int J Biol Macromol 135:864
Fais A, Era B, Asthana S, Sogos V, Medda R, Santana L, Uriarte E, Matos MJ, Delogu F, Kumar A (2018) Int J Biol Macromol 120:1286
Zhang T, Li S, Wang L, Sun Q, Wu Q, Zhang Y, Meng F (2017) Eur J Med Chem 141:362
Haziz FMU, Haque AR, Amirul AA, Shaheeda N, Razali RM (2016) Polyhedron 117:628
Haque AR, Haziz FMU, Al-Ashraf AA, Shaheeda N, Raz-ali RM (2016) Polyhedron 109:208
Haque AR, Hasanudin N, Iqbal AM, Ahmad A, Hashim S, Majid AA, Ahamed KBM (2013) J Coord Chem 66:3211
Haque AR, Budagumpi S, Zulikha ZH, Hasanudin N, Ahamed KBM, Majid AMSA (2014) Inorg Chem Commun 44:128
Yan X-Q, Wang Z-C, Zhang B, Qi P-F, Li G-G, Zhu H-L (2019) Molecules 24:1685
Göçer H, Akıncıoglu A, Goksu S, Gulcin I (2017) Arabian J Chem 10:398
Verpoorte JA, Mehta S, Edsall JT (1967) J Biol Chem 242:4221
Frisch MJ, Trucks GW, Schlegel HB, Scuseria GE, Robb MA, Cheeseman JR, Scalmani G, Barone V, Mennucci B, Petersson GA, Nakatsuji H, Caricato M, Li X, Hratchian HP, Izmaylov AF, Bloino J, Zheng G, Sonnenberg JL, Hada M, Ehara M, Toyota K, Fukuda R, Hasegawa J, Ishida M, Nakajima T, Honda Y, Kitao O, Nakai H, Vreven T, Montgomery JA, Orti JR, Peralta JE, Ogliaro F, Bearpark M, Heyd JJ, Brothers E, Kudin KN, Staroverov VN, Kobayashi R, Normand J, Raghavachari K, Rendell A, Burant JC, Iyengar SS, Tomasi J, Cossi M, Rega N, Millam JM, Klene M, Knox JE, Cross JB, Bakken V, Adamo C, Jaramillo J, Gomperts R, Stratmann RE, Yazyev O, Austin AJ, Cammi R, Pomelli C, Ochterski JW, Martin RL, Morokuma K, Zakrzewski VG, Voth GA, Salvador P, Dannenberg JJ, Dapprich S, Daniels AD, Farkas Ö, Foresman JB (2009) Gaussian 09, Revision E.01. Gaussian Inc, Wallingford, CT, USA
Dassault Systemes BIOVIA (2019) Discovery studio. Dassault Systems, San Diego, CA, USA
Acknowledgements
This study was financially supported by Inonu University Research Fund (Project Code: FYL-2019-1446 and FBG-2018-1569). The authors thank the Inonu University Faculty of Science Department of Chemistry for the spectroscopy and elemental analysis characterization of compounds.
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Türker, F., Noma, S.A.A., Aktaş, A. et al. The (NHC)PdBr2(2-aminopyridine) complexes: synthesis, characterization, molecular docking study, and inhibitor effects on the human serum carbonic anhydrase and serum bovine xanthine oxidase. Monatsh Chem 151, 1557–1567 (2020). https://doi.org/10.1007/s00706-020-02687-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00706-020-02687-2